Arterial stiffness and atrial fibrillation recurrence: another risk marker or a call for better management of concomitant disease?

J. R. de Groot; D. Linz

doi:10.1007/s12471-022-01678-8

Arterial stiffness and atrial fibrillation recurrence: another risk marker or a call for better management of concomitant disease?

J. R. de Groot^*, D. Linz

^*Corresponding author af dette arbejde

Physiology of circulation, kidney and lung

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

1 Citationer (Scopus)

11 Downloads (Pure)

Originalsprog	Engelsk
Tidsskrift	Netherlands Heart Journal
Vol/bind	30
Udgave nummer	4
Sider (fra-til)	187-189
ISSN	1568-5888
DOI	https://doi.org/10.1007/s12471-022-01678-8
Status	Udgivet - 2022

Bibliografisk note

Funding Information:
J.R. de Groot has received research grants through his institution from Atricure, Bayer, Boston Scientific, Daiichi Sankyo, Johnson & Johnson and Medtronic, and honoraria/speaker’s fees from AtriCure, Bayer, BIOTRONIK, CardioVasculair Onderwijs Instituut, Daiichi Sankyo, Medtronic, Novartis and Servier. D. Linz has received research grants through his institution from Bayer and Biosense Webster, and honoraria/speaker’s fees from Daiichi Sankyo, Medtronic, BIOTRONIK, Respicardia and Itamar Medical.

Adgang til dokumentet

10.1007/s12471-022-01678-8Licens: CC BY

FulltextForlagets udgivne version, 175 KBLicens: CC BY

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{3c103f95505d4c5395794fc9c627885f,

title = "Arterial stiffness and atrial fibrillation recurrence: another risk marker or a call for better management of concomitant disease?",

author = "{de Groot}, {J. R.} and D. Linz",

note = "Funding Information: J.R. de Groot has received research grants through his institution from Atricure, Bayer, Boston Scientific, Daiichi Sankyo, Johnson & Johnson and Medtronic, and honoraria/speaker{\textquoteright}s fees from AtriCure, Bayer, BIOTRONIK, CardioVasculair Onderwijs Instituut, Daiichi Sankyo, Medtronic, Novartis and Servier. D. Linz has received research grants through his institution from Bayer and Biosense Webster, and honoraria/speaker{\textquoteright}s fees from Daiichi Sankyo, Medtronic, BIOTRONIK, Respicardia and Itamar Medical.",

year = "2022",

doi = "10.1007/s12471-022-01678-8",

language = "English",

volume = "30",

pages = "187--189",

journal = "Netherlands Heart Journal",

issn = "1568-5888",

publisher = "Bohn Stafleu van Loghum",

number = "4",

}

TY - JOUR

T1 - Arterial stiffness and atrial fibrillation recurrence

T2 - another risk marker or a call for better management of concomitant disease?

AU - de Groot, J. R.

AU - Linz, D.

N1 - Funding Information: J.R. de Groot has received research grants through his institution from Atricure, Bayer, Boston Scientific, Daiichi Sankyo, Johnson & Johnson and Medtronic, and honoraria/speaker’s fees from AtriCure, Bayer, BIOTRONIK, CardioVasculair Onderwijs Instituut, Daiichi Sankyo, Medtronic, Novartis and Servier. D. Linz has received research grants through his institution from Bayer and Biosense Webster, and honoraria/speaker’s fees from Daiichi Sankyo, Medtronic, BIOTRONIK, Respicardia and Itamar Medical.

PY - 2022

Y1 - 2022

UR - http://www.scopus.com/inward/record.url?scp=85126100330&partnerID=8YFLogxK

U2 - 10.1007/s12471-022-01678-8

DO - 10.1007/s12471-022-01678-8

M3 - Journal article

C2 - 35258798

AN - SCOPUS:85126100330

SN - 1568-5888

VL - 30

SP - 187

EP - 189

JO - Netherlands Heart Journal

JF - Netherlands Heart Journal

IS - 4

ER -